華神科技(000790.SZ):星瑞藥業擬將上海凌凱5.4019%股份轉讓給陸茜
格隆匯5月8日丨華神科技(000790.SZ)公佈,公司於2025年5月6日召開第十三屆董事會第二十一次會議,審議通過了《關於子公司出售參股公司股權的議案》,同意公司子公司海南華神星瑞藥業科技有限公司(簡稱“星瑞藥業”)將持有的上海凌凱科技股份有限公司(簡稱“上海凌凱”)5.4019%股份以人民幣2億元轉讓給陸茜,本次交易完成後,星瑞藥業不再持有上海凌凱股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.